News

Implantation of the Aeson Total Artificial Heart — a device from Carmat designed to mimic the heart’s function — was able to help three advanced heart failure patients with pulmonary hypertension (PH) to become eligible for a heart transplant. The patients, who had previously been considered transplant-ineligible due…

Activation of an immune signaling molecule called STAT6 may lead to pulmonary hypertension (PH) in people with oxygen deprivation due to obstructive sleep apnea, according to a recent study in mice. Obstructive sleep apnea is a common sleep disorder characterized by chronic intermittent hypoxia, or repeated episodes of stopping…

An artificial intelligence (AI)-based algorithm is capable of detecting features of pulmonary hypertension (PH) by analyzing heart sounds recorded with a digital stethoscope, a study found. Eko Health developed the technology with the help of a $2.7 million National Institutes of Health (NIH) grant. The algorithm could…

Blocking GLS1, an enzyme that drives pro-inflammatory immune macrophages, reduces the signs and symptoms of pulmonary arterial hypertension (PAH) in rats, a study reports. “This study offers a fresh outlook upon understanding the role of macrophages in PAH and provides experimental evidence in developing targeted therapeutic strategies,” the researchers…

Anoikis, a form of programmed cell death, is involved in the development of chronic thromboembolic pulmonary hypertension (CTEPH), according to a genetic analysis study. Researchers identified two anoikis-related genes associated with CTEPH — PLAUR and HMOX1 — which may serve as diagnostic biomarkers or as…

Seralutinib, an inhaled therapy for pulmonary arterial hypertension (PAH) in the pipeline of Gossamer Bio, continues to reduce the resistance blood faces moving into the lungs when added to standard of care treatment for PAH, according to data from a long-term extension part of a Phase 2 clinical…

A single dose of the investigational therapy TX45 improved heart function and blood flow, or hemodynamics, in people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to interim results from a Phase 1b clinical trial. The part of the study involving PH-HFpEF patients is completely…

Merck announced that its Phase 3 clinical trial HYPERION, which had been testing Winrevair (sotatercept-csrk) in people with recently diagnosed pulmonary arterial hypertension (PAH), will be ended early — a move that will allow all study participants, including those who had been assigned to receive a placebo,…

Men with pulmonary arterial hypertension (PAH) have a larger right heart size and worse survival rates than women, independent of body size and functional status, a study reports. Moreover, sex-specific mortality risk thresholds, with higher risk indicated by a larger area of the right pulmonary artery, as measured by…

LungFit PH, a device developed by Beyond Air for administering nitric oxide (NO) therapy, has received marketing approval from the Australian Therapeutic Goods Administration (TGA), which will allow the company to market the device as a Class IIb medical device. NO causes blood vessels to relax and widen, lowering…

An imaging technique called 18F-FAPI PET may be able to detect the earliest signs of changes in blood vessel tissues that occur in pulmonary arterial hypertension (PAH), a new study reports. According to researchers, this novel approach, which uses positron emission tomography or PET imaging, may help…

People with pulmonary arterial hypertension (PAH) seen to be at an intermediate risk of death — whether in the low or high range of that middle-level risk — were more likely to have better outcomes when treated with Adempas (riociguat) than given a placebo in a Phase 3…